Abstract

Medical device manufacturers must continuously evaluate all clinical data available for their products marketed in Europe. With the European Medical Device Regulation 2017/745 coming into force in May 2021, manufacturers are required to assess available implant registry data as part of the clinical evaluation process. This new requirement will necessitate a closer collaboration between industry and registries to evaluate the safety and performance of high-risk devices. Medical writers should be aware of existing implant registries, understand what characteristics make a registry suitable to support regulatory requirements, and recognise both the value and the limitations of registries as a source of clinical evidence.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.